Category Archives: Neuroscience

Bill Yates Appointed Vice Chancellor for Research Protections – UPJ Athletics

Bill Yates has been appointed vice chancellor for research protections, where he will lead the units in the Office of Research Protections (ORP) which aids investigators in designing and performing research studies so they meet current ethical standards and conform to all applicable laws and regulations. His appointment is effective Jan. 1, 2021.

ORP supports key research-related committees at the University, including the Institutional Review Board, Institutional Animal Care and Use Committee, Conflict of Interest Committee, Radiation Safety Committee and Institutional Biosafety Committee, and also is responsible for oversight of research integrity.

Bill brings a strong sense of practical experience in research, and a commitment to provide service to the research community, said Senior Vice Chancellor for Research Rob A. Rutenbar.

I am delighted to continue to serve the University in this new role, said Yates. He has been serving in the role on an interim basis since September 2020, when George Huber retired from the position.

Yates also is a professor in the Department of Otolaryngology in Pitts School of Medicine, and holds a secondary appointment in the Department of Neuroscience in the Kenneth P. Dietrich School of Arts and Sciences. He has been awarded continuous R01 grant funding from the National Institutes of Health since 1990 to examine vestibular system influences on autonomic regulation. In addition, he is heavily engaged in teaching of undergraduate, graduate and medical students, and was awarded the Chancellors Distinguished Teaching Award in 2010.

Yates joined Pittin 1994 from The Rockefeller University in New York City. He received a Ph.D. degree in neuroscience from the University of Florida in 1986.

Go here to see the original:
Bill Yates Appointed Vice Chancellor for Research Protections - UPJ Athletics

Scientists show what loneliness looks like in the brain – Newswise

Newswise This holiday season will be a lonely one for many people as social distancing due to COVID-19 continues, and it is important to understand how isolation affects our health. A new study shows a sort of signature in the brains of lonely people that make them distinct in fundamental ways, based on variations in the volume of different brain regions as well as based on how those regions communicate with one another across brain networks.

A team of researchers examined the magnetic resonance imaging (MRI) data, genetics and psychological self-assessments of approximately 40,000 middle-aged and older adults who volunteered to have their information included in the UK Biobank: an open-access database available to health scientists around the world. They then compared the MRI data of participants who reported often feeling lonely with those who did not.

The researchers found several differences in the brains of lonely people. These brain manifestations were centred on what is called the default network: a set of brain regions involved in inner thoughts such as reminiscing, future planning, imagining and thinking about others. Researchers found the default networks of lonely people were more strongly wired together and surprisingly, their grey matter volume in regions of the default network was greater. Loneliness also correlated with differences in the fornix: a bundle of nerve fibres that carries signals from the hippocampus to the default network. In lonely people, the structure of this fibre tract was better preserved.

We use the default network when remembering the past, envisioning the future or thinking about a hypothetical present. The fact the structure and function of this network is positively associated with loneliness may be because lonely people are more likely to use imagination, memories of the past or hopes for the future to overcome their social isolation.

"In the absence of desired social experiences, lonely individuals may be biased towards internally-directed thoughts such as reminiscing or imagining social experiences. We know these cognitive abilities are mediated by the default network brain regions," says Nathan Spreng from The Neuro (Montreal Neurological Institute-Hospital) of McGill University, and the study's lead author. "So this heightened focus on self-reflection, and possibly imagined social experiences, would naturally engage the memory-based functions of the default network."

Loneliness is increasingly being recognized as a major health problem, and previous studies have shown older people who experience loneliness have a higher risk of cognitive decline and dementia. Understanding how loneliness manifests itself in the brain could be key to preventing neurological disease and developing better treatments.

"We are just beginning to understand the impact of loneliness on the brain. Expanding our knowledge in this area will help us to better appreciate the urgency of reducing loneliness in today's society," says Danilo Bzdok, a researcher at The Neuro and the Quebec Artificial Intelligence Institute, and the study's senior author.

###

This study was published in the journal Nature Communications on Dec. 15, 2020. It was partially funded by a grant to Spreng and Bzdok from the U.S. National Institute on Aging.

The Neuro

The Neuro - The Montreal Neurological Institute-Hospital - is a world-leading destination for brain research and advanced patient care. Since its founding in 1934 by renowned neurosurgeon Dr. Wilder Penfield, The Neuro has grown to be the largest specialized neuroscience research and clinical center in Canada, and one of the largest in the world. The seamless integration of research, patient care, and training of the world's top minds make The Neuro uniquely positioned to have a significant impact on the understanding and treatment of nervous system disorders. In 2016, The Neuro became the first institute in the world to fully embrace the Open Science philosophy, creating the Tanenbaum Open Science Institute. The Montreal Neurological Institute is a McGill University research and teaching institute. The Montreal Neurological Hospital is part of the Neuroscience Mission of the McGill University Health Centre. For more information, please visithttp://www.theneuro.ca

Go here to read the rest:
Scientists show what loneliness looks like in the brain - Newswise

FLiCRE: A New Tool for Revealing the Brain in Action – Technology Networks

A new molecular probe from Stanford University could help reveal how our brains think and remember. This tool, called Fast Light and Calcium-Regulated Expression or FLiCRE (pronounced "flicker"), can be sent inside any cell to perform a variety of research tasks, including tagging, recording and controlling cellular functions.

"This work gets at a central goal of neuroscience: How do you find the system of neurons that underlie a thought or cognitive process? Neuroscientists have been wanting this type of tool for a long time," said Alice Ting, professor of genetics in the Stanford School of Medicine and of biology in the School of Humanities and sciences, whose team co-led this work with the lab of Stanford psychiatrist and bioengineer, Karl Deisseroth.

In proof-of-concept experiments, detailed in a paper published Dec. 11 in Cell, the researchers used FLiCRE to take a snapshot of neural activity associated with avoidance behavior in mice. By coupling the FLiCRE snapshot with RNA sequencing, they discovered that these activated neurons primarily belonged to a single cell type, which was inaccessible using genetic tools alone. They then used FLiCRE in combination with an opsin - a protein for controlling neural activity with light developed by Deisseroth - to reactivate those same neurons a day later, which led the mice to avoid entering a certain room. The brain region the researchers studied, called the nucleus accumbens, is thought to play an important role in human psychiatric diseases, including depression.

Modular molecular technology

FLiCRE is made up of two chains of molecular components that respond to the presence of blue light and calcium. This light sensitivity allows the researchers to precisely control the timing of their experiments, and calcium is an almost-universal indicator of cell activity. To get FLiCRE inside a cell, the researchers package it, in two parts, within a harmless virus. One part of FLiCRE attaches to the cell membrane and contains a protein that can enter the cell's nucleus and drive expression of whatever gene the researchers have selected. The other part of FLiCRE is responsible for freeing the protein under certain specific conditions, namely if the concentration of calcium is high and the cell is bathed in blue light.

Whereas existing tagging techniques require hours to activate, the FLiCRE tagging process takes just minutes. The researchers also designed FLiCRE so that they can use standard genetic sequencing to find the cells in which FLiCRE activated. This allows them to study tens of thousands of cells at once, while other techniques tend to require the analysis of multiple microscopic images that each contain hundreds of cells.

In one series of experiments, the researchers injected FLiCRE into cells in the nucleus accumbens and used an opsin to activate a neural pathway associated with avoidance behavior in the mice. Once the calcium in FLiCRE-containing cells spiked - the cellular indication that the mouse is avoiding something - the cells glowed a permanent red that was visible through a microscope. The researchers also sequenced the RNA of the cells to see which ones contained the fluorescent protein, producing a cell-by-cell record of neural activity.

"One goal was to map how brain regions are connected to each other in living animals, which is a really hard problem," said Christina Kim, a postdoctoral scholar in genetics at Stanford and co-lead author of the paper. "The beauty of FLiCRE is that we can pulse and activate neurons in one region and then record all of the connected downstream neurons. It is a really cool way to look at long-range brain activity connections."

In the next experiments, the researchers used the cellular activity map from the first experiments. They also adjusted FLiCRE so that the protein expressed the opsin protein, which can be controlled by orange light to alter neuronal activity. After activating FLiCRE in the cells, the researchers sent orange light through the fiber optic implant whenever the mice would enter a certain room. In response, the mice steered clear of that room, indicating that FLiCRE had indeed located cells in the brain that drive avoidant behavior.

A dream project

The development and testing of FLiCRE combined chemistry, genetics, biology and neuroscience, and many specialties within those disciplines. As a result, the tool has a wide range of possible applications, including in cells outside the brain, the researchers say.

"I moved to Stanford in 2016 with the hope of being able to carry out extremely interdisciplinary and collaborative projects such as this," said Ting. "This project has been one of the most rewarding aspects of my move to Stanford - seeing something this challenging and ambitious actually work out."

The researchers are now working on additional versions of FLiCRE, with a goal of streamlining the process. They are hoping to simplify its structure and also make it capable of working with other biochemical events, such as protein interactions or neurotransmitter release.

Reference: Kim CK, Sanchez MI, Hoerbelt P, et al.A Molecular Calcium Integrator Reveals a Striatal Cell Type Driving Aversion. Cell. 2020. doi:10.1016/j.cell.2020.11.015

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Visit link:
FLiCRE: A New Tool for Revealing the Brain in Action - Technology Networks

Science Podcast Cohosted by BU Neuroscientist Brings Research to Listeners around the World – BU Today

Shen Ning and Mehdi Jorfi are on a mission to make cutting-edge medical research and impactful scientific discoveries accessible to everyone. After a year of hosting Science Rehashed, a podcast dedicated to the life sciences, they have become experts at dissecting, translating, and communicating meaningful science to students and young professionals across the globe who cant afford pay-for-access top-tier journals and peer-reviewed papers.

Many students outside of first-world countries have limited resources when it comes to accessing the most current scientific research and journals, says Ning, Science Rehashed cohost and a Boston University MD/PhD candidate studying neuroscience. Ning met Jorfi while collaborating on research at Massachusetts General Hospital (MGH) in 2019, when Jorfi approached her with the idea to start a science podcast.

While growing up and attending university in Iran, Jorfi had noticed the dearth of up-to-date research and resources in his local library, a big problem for an aspiring scientist. Ning, who grew up in China and moved to the United States at eight years old, also understood the challenges of being in a less resource-rich country, she says. Jorfi, now a faculty member at Harvard Medical School and MGH, believed creating a freely available podcast for young aspiring scientists abroad was a perfect way to fill this need.

Others quickly saw the value such a podcast would deliver, too. Within the first month of joining forces, Ning and Jorfi received funding from Innovate@BUs Innovation Pathway program, providing them with financial and creative support, as well as resources to communications mentors and trainers.

In 25- to 40-minute episodes, Ning and Jorfi have informal conversations with lead authors on high-impact papers published in peer-reviewed journals, releasing new episodes every three weeks. They have interviewed dozens of life scientists, ranging from biomedical engineers to physicians to biologists, and have even interviewed COVID-19 patients about their firsthand experiences. Episodes have garnered over 5,000 downloads, with listeners tuning in from over 75 countries. This year, their growing team of volunteer audio engineers and social media gurus won the 2020 Life Sciences & Healthcare Nonprofit Pitch Challenge, scoring them $2,500 to continue building and expanding their reach.

Im really happy that Ive been involved and have met amazing, incredible, inspiring people along my journey, says Ning. We have a wonderful team. Working on this on the side, in addition to your normal job or schooling, can be a lot. But with a really great, effective, complementary team, it doesnt feel like work at all.

The Brink caught up with Ning and Jorfi to hear how the podcast is going, what it takes to pull off a podcast, and how they communicate complex science effectively for a broad audience.

Q&AWith Shen Ning and Mehdi Jorfi

Jorfi: I sincerely believe that science and education is a right and not a privilege. But the reality is that many brilliant students and scientists worldwide, particularly those who live in emerging countries, start their journey at a disadvantage. I faced this reality while growing up in Iran attending university, where resources to top journals were scarce. The only resources available were outdated papers buried in the back of the stacks in the library from over 10 years ago. Years later, and many gray hairs later, I pursued my graduate degree in Switzerland and postdoctoral training at MIT and Harvard, where I was able to freely explore the latest science breakthroughs without any limitations. Because of this, I wanted to give back by helping future young scientists worldwide overcome the hurdles I experienced. One day I had an epiphany while listening to podcasts and reflecting back on my life, and Science Rehashed was born.

Ning: Mehdi approached me the next day and asked, what do you think about starting a science podcast? He explained his experience in Iran, and how itll be really helpful for people in those countries to have a resource that presents the most up-to-date science of the time around the world. And I was like, well, thats a really great point and a really great need we definitely need to address.

We started talking about our experience and strengthsI have a medicine background, with biology, neuroscience, and a little bit of bioengineering, and he has a background in biomedical engineering, chemistry, and also neuroscienceand we realized we can cover quite a few topics, but with a focus on life sciences and a touch of medicine. We wanted to choose papers that have a very high impact or have the potential to have a clinical or scientific impact in the upcoming 10 years. So, we started looking at top-notch journals, and we started inviting people. We recorded three episodes just to start off, and got it figured out. And then, we started working alongside Sofia Nastri, whos another BU student who graduated last year. Shes our lead audio engineer and shes a very talented scientist, too.

Ning: Yeah, we aimed pretty big in the beginning, just because one of the marketing strategies [for a podcast] is, once you get a few big people, then the rest follows.

Jorfi: There are millions of scientists and students in developing countries without the same resources as we have in Boston due to the lack of subscriptions to scientific journals at their institutions. Plus, we know how vital it is to sift through hundreds of scientific journals to stay up-to-date on the most pressing issues, yet a barrier of scientific jargon dilutes the main findings of studies.

Ning: With COVID-19, its becoming very apparent how important it is for the public to understand [research and the scientific process]. Before COVID-19, [the gene-editing technology known as] CRISPR was a big topic for public health and an ethical issueregarding [genetically engineered] babies and whether it should be legal or illegal. Especially with how quickly the life sciences are evolving and advancingalmost outpacing the ability for us to make the laws and policies [to regulate new technologies and therapeutics]its especially important.

Ning: Weve been working with a number of coaches who guide us to figure out how to create a narrative for each episode, and how to screen our guests so that the guests themselves are not difficult to understand in terms of jargon. Weve picked up a number of different communication skills, as well as story writing skills to include into our podcast. There are so many [specialized] words in science, abbreviations, and terminologies that for Mehdi and me, at this point, we dont even think about it. But, most people would be like, Okay, what are nucleotides? Lets talk about that! So, that has been a challenge, because sometimes we ask questions without initially framing [the subject] in a way that most people would understand. I go back and listen to some episodes and I can see how weve been improving. It takes weeks to go through the story, figure out which pieces we want to pull, whether we need to rerecord or explain jargon that may be very hard to understand for the general public. When youre listening to a podcast or music, sometimes you dont always pay attention 100 percent of the time, so its okay to repeat certain things that youve said before and, in fact, its probably encouraged. Weve been learning to rephrase things or ask the same question with different words. But coming from a science background, it has been nice because were able to have very natural conversations with the scientists. Anyone should be able to understand, if not the whole picture, at least lets say 70 to 80 percent of it.

One of our series, the 360 Perspective series, is really geared towards the general public and gives a holistic perspective on one topic or one particular public health concern. For the COVID-19 episode, we brought in patients, physicians from Italy, physicians in the United States, scientists who study COVID-19. And so we talked to them about their thoughts and their expertise, so the public can gain a better perspective of what was going on.

Jorfi: One of my favorite episodes is COVID-19: A 360 Perspective.

Ning: The first episode has a good introduction between me and Mehdi about the motivation behind the show, and it is an episode that was right up my alley. [The episode is] called the 40 Hertz Idea, with [our first guest] Dr. Li-Huei Tsai. Shes a leading female scientist in a field that is relatively male-dominated. Her work revolves around using 40 hertz of audio or visual stimulation to treat Alzheimers disease. I read [her] paper [describing the method] and followed the work over a number of years, so it was very exciting for me to hear the whole story from the person herself.

Ning: I think it would be really awesome to have Mayim Bialik from The Big Bang Theory, because she is a neuroscientist by training. That would be really cool as a part of our Wonder WomXn in Science & Engineering series that we just started.

Jorfi: We plan to continue to pursue our growth in the United States and United Kingdom, too, and we are aggressively targeting emerging countries with less available resources. Our goal is really to ensure that no aspiring individual will give up on science because of the lack of resources, because that should be the last challenge any scientists should have to face on their journey.

Ning: One of the things we did to increase our reach in the countries were targeting is that we started a Science Rehashed ambassador program, where anyonestudents, postdocs, early career scientistscan promote the podcast and introduce this resource to their peers and other people who might be looking for something like this. Right now, we have people from Iran, Peru, Switzerland, Turkey, Italy, Norway, India, and we have a US ambassador at Northeastern University. For some countries, there are language and cultural barriers that we need to overcome to capture our target audience. We are also focused on community outreach locally. So, getting involved with local youth programs and associations. Theres a huge number of organizations in Boston advocating for women in STEM and I think we want to join in that effort. Were looking into figuring out partnerships, either with other nonprofit organizations or venture capitals, biotech or pharma, that share the same type of mission or want to support us in our mission.

Interview has been edited and condensed for clarity.

View original post here:
Science Podcast Cohosted by BU Neuroscientist Brings Research to Listeners around the World - BU Today

Cerevel Therapeutics to Host Inaugural Virtual R&D Event – GlobeNewswire

Event will focus on CVL-865, the Phase 2 GABA Positive Allosteric Modulator, and include an overview of key preclinical programs

Live webcast scheduled for Thursday, January 28 from 9:00 to 11:00 a.m. EST

CAMBRIDGE, Mass., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain totreatneurosciencediseases, announced it will host the first in a series of virtual R&D events on Thursday, January 28 from 9:00 to 11:00 a.m. EST. Hosted as a live webcast, Cerevel will lead an in-depth discussion of CVL-865, its Phase 2 GABA positive allosteric modulator (GABA PAM) as well as provide an overview of leading preclinical / early clinical assets. Subsequent R&D events dedicated to additional portfolio programs will be announced at a future time.

CVL-865 is currently being studied in two clinical trials, including the Phase 2 REALIZE trial evaluating the compound as an adjunctive therapy in adults with drug-resistant focal onset seizures, and a Phase 1 proof-of-principle trial for acute anxiety in healthy volunteers. Data from the REALIZE trial are expected in the second half of 2022 and data from the Phase 1 trial for acute anxiety are expected in the second half of 2021. This event is intended to provide a detailed look at the science behind the current clinical program, with time for questions.

The live webcast can be accessed on the investor relations section of the Cerevel Therapeutics website here. A replay will be available in the same section of the companys website for approximately 90 days.

About CVL-865CVL-865 is a subtype selective positive allosteric modulator (PAM) that targets GABAA receptors containing 2/3/5 subunits. It is structurally differentiated from classical benzodiazepines and minimizes activity at 1-containing receptors, which is believed to help mitigate many of the adverse events associated with benzodiazepines. To date, CVL-865 has been evaluated in 289 patients and healthy volunteers across nine clinical trials, with results showing it to be generally well-tolerated. A Phase 2 single-dose trial demonstrated robust anticonvulsant activity in patients with photosensitive epilepsy (a type of epilepsy in which seizures are triggered by flashing lights), with six of seven patients treated with CVL-865 experiencing complete suppression of intermittent photic stimulation (IPS), a characteristic epileptiform discharge shown on electroencephalograms (EEGs). For more information about the Phase 2 clinical trial, please visit https://realizestudy.com.

About Cerevel TherapeuticsCerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. Cerevel Therapeutics has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinsons disease and substance use disorder. Headquartered in Cambridge, Mass., Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions. For more information, visit http://www.cerevel.com.

Special Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements that are based on managements beliefs and assumptions and on information currently available to management. In some cases, you can identify forward-looking statements by the following words: may, will, could, would, should, expect, intend, plan, anticipate, believe, estimate, predict, project, potential, continue, ongoing or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements about the potential attributes and benefits of our product candidates, the format and timing of our product development activities and clinical trials, including the expected timing of data announcements. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. Actual performance and results may differ materially from those projected or suggested in the forward-looking statements due to various risks and uncertainties, including, among others: that clinical trial results may not be favorable; uncertainties inherent in the product development process (including with respect to the timing of results and whether such results will be predictive of future results); the impact of COVID-19 on the timing, progress and results of ongoing or planned clinical trials; other impacts of COVID-19, including operational disruptions or delays or to our ability to raise additional capital; whether and when, if at all, our product candidates will receive approval from the FDA or other regulatory authorities, and for which, if any, indications; competition from other biotechnology companies; uncertainties regarding intellectual property protection; and other risks identified in our SEC filings, including those under the heading Risk Factors in our definitive proxy statement/prospectus filed with the SEC on October 7, 2020. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

Media Contact:Rachel EidesW2O purereides@purecommunications.com

Investor Contact:Matthew CalistriCerevel Therapeuticsmatthew.calistri@cerevel.com

See more here:
Cerevel Therapeutics to Host Inaugural Virtual R&D Event - GlobeNewswire

Global Neuroscience Antibodies and Assays Market 2020 | (COVID 19 Analysis) Offered In New Most recent Research Report with Forecast 2026 – The…

The globalNeuroscience Antibodies and Assaysmarket research report offers all the vital data in the domain. The latest report assists new bees as well as established market participants to analyze and predict the Neuroscience Antibodies and Assays market at the regional as well as global level. It covers the volume [k MT] as well as revenues [USD Million] of the global Neuroscience Antibodies and Assays market for the estimated period. Numerous key players BioLegend, Siemens, GenScript, Bio-Rad, Thermo Fisher Scientific, Rockland Immunochemicals, Abcam, Tecan, Merck KGaA, Santa Cruz Biotechnology, Cell Signaling Technology, F. Hoffmann-La Roche are dominating the global Neuroscience Antibodies and Assays market. These players hold the majority of share of the global Neuroscience Antibodies and Assays market.

Sample of global Neuroscience Antibodies and Assays Market Report at::https://www.marketresearchstore.com/report/global-neuroscience-antibodies-and-assays-market-report-2020-749830#RequestSample

The data presented in the global Neuroscience Antibodies and Assays market offers budding opportunities, which help users to make strategic moves and prosper their business. The report highlights the impact of numerous factors that might result in obstructing or propelling the Neuroscience Antibodies and Assays market at global as well as local level. The global Neuroscience Antibodies and Assays market research report offers the summary of key players dominating the market including several aspects such as their financial summary, business strategy, and most recent developments in these firms.

Key points of the global Neuroscience Antibodies and Assays market

Theoretical analysis of the global Neuroscience Antibodies and Assays market stimulators, products, and other vital facets Recent, historical, and future trends in terms of revenue and market dynamics are reported Pin-point analysis of the competitive market dynamics and investment structure is predicted to grow Future market trends, latest innovations, and various business strategies are reported Market dynamics include growth influencers, opportunities, threats, challenges, and other crucial facets

The global Neuroscience Antibodies and Assays market research report offers users with an all-inclusive package of market analysis that includes current market size, expansion rate, and value chain analysis. The global Neuroscience Antibodies and Assays market is segmented on a regional basis Europe, North America, Latin America, Asia Pacific, and Middle East & Africa as well. To offer a comprehensive view and competitive outlook of the global Neuroscience Antibodies and Assays market, our review team employs numerous methodological procedures, for instance, Porters five forces analysis.

Ask Any Kind of Query Before Purchasing the Report Here::https://www.marketresearchstore.com/report/global-neuroscience-antibodies-and-assays-market-report-2020-749830#InquiryForBuying

This research report includes the analysis of various Neuroscience Antibodies and Assays market segments {Consumables, Instruments}; {Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Hospitals & Diagnostic Centers}. The bifurcation of the global market is done based on its present and prospective inclinations. The regional bifurcation involves the present market scenario in the region along with the future projection of the global Neuroscience Antibodies and Assays market. The global market report offers an overview of expected market conditions due to changes in the technological, topographical, and economic elements.

Questions answered in the report include

1. What is the expected market size by the end of the forecast period?2. What are the major factors initiating the global Neuroscience Antibodies and Assays market growth?3. What are the latest developments and trending market strategies that are influencing the growth of the Neuroscience Antibodies and Assays market?4. What are the key outcomes of the Neuroscience Antibodies and Assays market developments?5. Who are the key players in the market?6. What are the opportunities and challenges faced by the key players?

Read Detailed Index of full Research Study at:https://www.marketresearchstore.com/report/global-neuroscience-antibodies-and-assays-market-report-2020-749830

Key Reasons for Purchasing Global Neuroscience Antibodies and Assays Market Report

New approaches and latest development trend that describe the structure of the market Advanced market breakdown structure Historical data and future market scope In-depth market analysis based on statistics, growth stimulators, and market developments Statistical data representation through figurative, numerical, and theoretical elaboration Report provides insight of the business and sales activities

Read more:
Global Neuroscience Antibodies and Assays Market 2020 | (COVID 19 Analysis) Offered In New Most recent Research Report with Forecast 2026 - The...

Is neuroscience the key to protecting AI from adversarial attacks? – TechTalks

This article is part of ourreviews of AI research papers, a series of posts that explore the latest findings in artificial intelligence.

Deep learning has come a long way since the days it could only recognize hand-written characters on checks and envelopes. Today, deep neural networks have become a key component of many computer vision applications, from photo and video editors to medical software and self-driving cars.

Roughly fashioned after the structure of the brain, neural networks have come closer to seeing the world as we humans do. But they still have a long way to go and make mistakes in situations that humans would never err.

These situations, generally known as adversarial examples, change the behavior of an AI model in befuddling ways. Adversarial machine learning is one of the greatest challenges of current artificial intelligence systems. They can lead machine learning models failing in unpredictable ways or becoming vulnerable to cyberattacks.

Creating AI systems that are resilient against adversarial attacks has become an active area of research and a hot topic of discussion at AI conferences. In computer vision, one interesting method to protect deep learning systems against adversarial attacks is to apply findings in neuroscience to close the gap between neural networks and the mammalian vision system.

Using this approach, researchers at MIT and MIT-IBM Watson AI Lab have found that directly mapping the features of the mammalian visual cortex onto deep neural networks creates AI systems that are more predictable in their behavior and more robust to adversarial perturbations. In a paper published on the bioRxiv preprint server, the researchers introduce VOneNet, an architecture that combines current deep learning techniques with neuroscience-inspired neural networks.

The work, done with help from scientists at the University of Munich, Ludwig Maximilian University, and the University of Augsburg, was accepted at the NeurIPS 2020, one of the prominent annual AI conferences, which will be held virtually this year.

The main architecture used in computer vision today is convolutional neural networks (CNN). When stacked on top of each other, multiple convolutional layers can be trained to learn and extract hierarchical features from images. Lower layers find general patterns such as corners and edges, and higher layers gradually become adept at finding more specific things such as objects and people.

In comparison to the traditional fully connected networks, ConvNets have proven to be both more robust and computationally efficient. There remain, however, fundamental differences between the way CNNs and the human visual system process information.

Deep neural networks (and convolutional neural networks in particular) have emerged as surprising good models of the visual cortexsurprisingly, they tend to fit experimental data collected from the brain even better than computational models that were tailor-made for explaining the neuroscience data, David Cox, IBM Director of MIT-IBM Watson AI Lab, told TechTalks. But not every deep neural network matches the brain data equally well, and there are some persistent gaps where the brain and the DNNs differ.

The most prominent of these gaps are adversarial examples, in which subtle perturbations such as a small patch or a layer of imperceptible noise can cause neural networks to misclassify their inputs. These changes go mostly unnoticed to the human eye.

It is certainly the case that the images that fool DNNs would never fool our own visual systems, Cox says. Its also the case that DNNs are surprisingly brittle against natural degradations (e.g., adding noise) to images, so robustness in general seems to be an open problem for DNNs. With this in mind, we felt this was a good place to look for differences between brains and DNNs that might be helpful.

Cox has been exploring the intersection of neuroscience and artificial intelligence since the early 2000s, when he was a student of James DiCarlo, neuroscience professor at MIT. The two have continued to work together since.

The brain is an incredibly powerful and effective information processing machine, and its tantalizing to ask if we can learn new tricks from it that can be used for practical purposes. At the same time, we can use what we know about artificial systems to provide guiding theories and hypotheses that can suggest experiments to help us understand the brain, Cox says.

For the new research, Cox and DiCarlo joined Joel Dapello and Tiago Marques, the lead authors of the paper, to see if neural networks became more robust to adversarial attacks when their activations were similar to brain activity. The AI researchers tested several popular CNN architectures trained on the ImageNet data set, including AlexNet, VGG, and different variations of ResNet. They also included some deep learning models that had undergone adversarial training, a process in which a neural network is trained on adversarial examples to avoid misclassifying them.

The scientist evaluated the AI models using the BrainScore metric, which compares activations in deep neural networks and neural responses in the brain. They then measured the robustness of each model by testing it against white-box adversarial attacks, where an attacker has full knowledge of the structure and parameters of the target neural networks.

To our surprise, the more brain-like a model was, the more robust the system was against adversarial attacks, Cox says. Inspired by this, we asked if it was possible to improve robustness (including adversarial robustness) by adding a more faithful simulation of the early visual cortexbased on neuroscience experimentsto the input stage of the network.

To further validate their findings, the researchers developed VOneNet, a hybrid deep learning architecture that combines standard CNNs with a layer of neuroscience-inspired neural networks.

The VOneNet replaces the first few layers of the CNN with the VOneBlock, a neural network architecture fashioned after the primary visual cortex of primates, also known as the V1 area. This means that image data is first processed by the VOneBlock before being passed on to the rest of the network.

The VOneBlock is itself composed of a Gabor filter bank (GFB), simple and complex cell nonlinearities, and neuronal stochasticity. The GFB is similar to the convolutional layers found in other neural networks. But while classic neural networks with random parameter values and tune them during training, the values of the GFB parameters are determined and fixed based on what we know about activations in the primary visual cortex.

The weights of the GFB and other architectural choices of the VOneBlock are engineered according to biology. This means that all the choices we made for the VOneBlock were constrained by neurophysiology. In other words, we designed the VOneBlock to mimic as much as possible the primate primary visual cortex (area V1). We considered available data collected over the last four decades from several studies to determine the VOneBlock parameters, says Tiago Marques, PhD, PhRMA Foundation Postdoctoral Fellow at MIT and co-author of the paper.

While there are significant differences in the visual cortex of different primate, there are also many shared features, especially in the V1 area. Fortunately, across primates differences seem to be minor and in fact there are plenty of studies showing that monkeys object recognition capabilities resemble those of humans. In our model with used published available data characterizing responses of monkeys V1 neurons. While our model is still only an approximation of primate V1 (it does not include all known data and even that data is somewhat limited there is a lot that we still do not know about V1 processing), it is a good approximation, Marques says.

Beyond the GFB layer, the simple and complex cells in the VOneBlock give the neural network flexibility to detect features under different conditions. Ultimately, the goal of object recognition is to identify the existence of objects independently of their exact shape, size, location and other low-level features, Marques says. In the VOneBlock it seems that both simple and complex cells serve complementary roles in supporting performance under different image perturbations. Simple cells were particularly important for dealing with common corruptions while complex cells with white box adversarial attacks.

One of the strengths of the VOneBlock is its compatibility with current CNN architectures. The VOneBlock was designed to have a plug-and-play functionality, Marques says. That means that it directly replaces the input layer of a standard CNN structure. A transition layer that follows the core of the VOneBlock ensures that its output can be made compatible with rest of the CNN architecture.

The researchers plugged the VOneBlock into several CNN architectures that perform well on the ImageNet data set. Interestingly, the addition of this simple block resulted in considerable improvement in robustness to white-box adversarial attacks and outperformed training-based defense methods.

Simulating the image processing of primate primary visual cortex at the front of standard CNN architectures significantly improves their robustness to image perturbations, even bringing them to outperform state-of-the-art defense methods, the researchers write in their paper.

The model of V1 that we added here is actually quite simplewere only altering the first stage of the system, while leaving the rest of the network untouched, and the biological fidelity of this V1 model is still quite simple, Cox says, adding that there is a lot more detail and nuance one could add to such a model to make it better match what is known about the brain.

Simplicity is strength in some ways, since it isolates a smaller set of principles that might be important, but it would be interesting to explore whether other dimensions of biological fidelity might be important, he says.

The paper challenges a trend that has become all too common in AI research in the past years. Instead of applying the latest findings about brain mechanisms in their research, many AI scientists focus on driving advances in the field by taking advantage the availability of vast compute resources and large data sets to train larger and larger neural networks. And as weve discussed in these pages before, that approach presents many challenges to AI research.

VOneNet proves that biological intelligence still has a lot of untapped potential and can address some of the fundamental problems AI research is facing. The models presented here, drawn directly from primate neurobiology, indeed require less training to achieve more human-like behavior. This is one turn of a new virtuous circle, wherein neuroscience and artificial intelligence each feed into and reinforce the understanding and ability of the other, the authors write.

In the future, the researchers will further explore the properties of VOneNet and the further integration of discoveries in neuroscience and artificial intelligence. One limitation of our current work is that while we have shown that adding a V1 block leads to improvements, we dont have a great handle onwhyit does, Cox says.

Developing the theory to help understand this why question will enable the AI researchers to ultimately home in on what really matters and to build more effective systems. They also plan to explore the integration of neuroscience-inspired architectures beyond the initial layers of artificial neural networks.

Says Cox, Weve only just scratched the surface in terms of incorporating these elements of biological realism into DNNs, and theres a lot more we can still do. Were excited to see where this journey takes us.

Here is the original post:
Is neuroscience the key to protecting AI from adversarial attacks? - TechTalks

Innovative Companies Diving into The Neuro Market Ahead of 2021 – BioSpace

With the expected Emergency Use Authorization (EUA) of Pfizer-BioNTech and Modernas COVID-19 vaccines providing hope that the COVID-19 pandemic will soon be resolved, 2021 is going to need a new primary healthcare campaign. Could it come from the field of neuroscience?

It will if the following five companies, which all launched this year with Series A financing, have anything to say about it.

Vigil Neuroscience

Led by industry veteran Ivana Magovevi-Liebisch, Vigil Neuroscience is developing a pipeline of precision-based therapies to combat both rare and common neurodegenerative diseases by restoring the vigilance of microglia.

A type of neuroglia located throughout the brain and spinal cord, microglia are the first line of immune defense for the central nervous system (CNS). As they are responsible for detecting plaques, damaged or unnecessary neurons, synapses, and infections, their inefficiency can lead to neuroinflammatory, neuropsychiatric, and neurodegenerative diseases, including Epilepsy, Parkinsons disease Multiple Sclerosis, and many types of dementia.

Vigils pipeline strategy is to target these diseases by combining a high-level understanding of microglia physiology, disease genotyping, and patient phenotyping to identify specific genetic variations associated with microglial dysfunction.

Vigils $50 million Series A financing, completed this week, was powered by Atlas Ventures and Northpond Ventures, and includes participating investors Hatteras Partners and Alexandria Venture Investments. Atlas cofounded, seeded and incubated Vigil, with pre-clinical stage assets in-licensed from Amgen Inc., which will remain a key shareholder.

SciNeuro Pharmaceuticals

SciNeuro Pharmaceuticals was also born this week, launched by Lilly Asia Ventures Fund and Arch Venture Partners, co-leaders of its $100 million Series A financing.

The financing advances the establishment of a robust and innovative CNS pipeline, focusing initially on the Greater China region.

One in every six people in China is living with a CNS condition, yet there are relatively few effective treatments available today, underscoring the urgent need to develop and deliver novel, effective therapies. The impact of CNS diseases extends beyond patients to their families and society as well, said SciNeuro Founder and chief executive officer, Min Li, Ph.D., in a statement.

Li is a prominent neuroscientist and former professor at Johns Hopkins Medicine. His company, which also includes Qiuqing Ang, M.D., Ph.D. as chief medical officer, and Danny Chen, Ph.D. as SVP & Head of Translational Science, will be particularly focused on CNS diseases where there is a major unmet need.

Genesis Therapeutics

Spun out of CEO and co-founder Evan Feinbergs breakthrough artificial Intelligence (AI) research at Stanford Universitys Pande Lab, Genesis Therapeutics is applying the resulting influential PotentialNet neural network algorithm to unify AI and biotech against a range of diseases with unmet needs.

Artificial intelligence holds immense promise to catalyze the development of the next generation of highly selective, orally bioavailable molecules, with reduced side effects, for the most impactful drug targets, Feinberg said at the time of the launch.

Genesis went public on December 2 in a round of $52 million Series A financing led by Rock Springs Capital. Dr. Kris Jenner of Rock Springs, who joins Genesis board of directors, is a renowned healthcare investor who has invested in several successful biotech companies.

Libra Therapeutics

California-based Libra Therapeutics launched in September with $29 million in Series A financing, co-led by Boehringer Ingelheim Venture Fund (BIVF), Epidarex Capital and Sant.

Libra, which means balance when translated to English, hopes to restore balance to the brains neurons. The company plans to do this by developing drugs that eliminate protein aggregation by either reducing the production of toxic proteins or removing them after the fact through autophagy.

Its like taking out the trash. It clears out the toxic proteins that build up in the neuron, thereby allowing the neuron to function properly, said Libra President and CEO Isaac Veinbergs, formerly of Acadia Pharmaceuticals and Sanofi.

Libra will use this approach, along with the $29 million infusion, to develop novel small molecule drug candidates for the treatment of neurodegenerative diseases.

Tranquis Therapeutics

An immuno-neurology company with a focus on neurodegenerative and aging-related diseases,Tranquis Therapeutics beat the aforementioned four to the show, launching on July 9 with $30 million in Series A funding, led by Remiges Ventures and SR One.

Tranquis platform is based on the groundbreaking work of its scientific founder, Professor Edgar Engleman, M.D., and his team at Stanford University, which posits that myeloid immune cell dysfunction underlies a variety of nervous system disorders.

The company is developing small molecule therapeutic candidates that cross the blood-brain barrier to target the underlying myeloid immune cell dysfunction associated with many CNS diseases.

While its original work focused on orphan diseases such as Frontotemporal Dementia and Amyotrophic Lateral Sclerosis, the team, led by President and CEO Sanjay Kakkar, M.D., will branch out to join the fight against more widespread illnesses, Parkinsons and Alzheimers.

For our lead program, TQS-168, we have demonstrated in vitro the ability to restore a key metabolic pathway we have shown is dysfunctional in the myeloid immune cells of patients with neurodegenerative diseases, as well as highly encouraging in vivo effects in challenging neurodegenerative disease models, Kakkar said at the time of the launch.

Most read today on BioSpace:

More here:
Innovative Companies Diving into The Neuro Market Ahead of 2021 - BioSpace

Cerevel Therapeutics Announces the Appointment of Dr. Ruth McKernan to its Board of Directors – GlobeNewswire

CAMBRIDGE, Mass., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain totreatneurosciencediseases, announced today that it has added Ruth McKernan, Ph.D., CBE, FMedSci, to serve as an independent member of its Board of Directors. Dr. McKernan currently serves as a venture partner with SV Health Investors, LLP, a global investment firm and specialist healthcare fund manager, where she supports companies that create new medicines for treating neurodegenerative disorders. With over 25 years of academic, research and commercial experience in the pharmaceutical industry, Dr. McKernan also serves as chairperson of the BioIndustry Association, a trade association for innovative life sciences in the United Kingdom, and as a trustee of Alzheimers Research UK, the countrys leading dementia research charity.

Dr. McKernan is an outstanding scientific leader with deep expertise in the biopharmaceutical industry and she will bring a wealth of knowledge and experience in neuroscience disorders to our board, said Tony Coles, M.D., chief executive officer and chairperson of Cerevel Therapeutics. Dr. McKernans guidance will help us as we seek to innovate the treatment landscape and bring new therapies to individuals facing some of the most vexing diseases including schizophrenia, epilepsy and Parkinsons disease.

I am honored to join the board of Cerevel, a neuroscience company that is working hard to bring new treatments to patients, said Dr. McKernan. Cerevel aspires to be the premier neuroscience company, and I look forward to contributing to the realization of that goal.

About Dr. Ruth McKernanDr. McKernans distinguished career has spanned the academic, business and government worlds. She has over 25 years of research and commercial experience in the pharmaceutical industry, including leading research units in the United Kingdom and the United States. Currently, Dr. McKernan is a venture partner with SV Health Investors, LLP, a global investment firm focused on the healthcare industry. At SV, Dr. McKernan focuses on companies that create new medicines for treating neurodegenerative disorders, including AstronauTx, a UKbased biotechnology company for which she serves as chairperson. She also serves as chairperson of the BioIndustry Association, a trade association for innovative life sciences in the United Kingdom, and as a trustee of Alzheimers Research UK.

Previously, Dr. McKernan served in a variety of senior leadership roles while at Pfizer, including as vice president, chief scientific officer of Regenerative Medicine, and chief scientific officer of Neusentis. In those roles, she initiated multiple neuroscience partnerships, acquisitions and spinouts and played an active part in taking more than 10 compounds into the clinic. Prior to Pfizer, Dr. McKernan served in multiple senior positions at Merck over the course of an 18-year tenure at the company. As a neuroscientist, Dr. McKernan has over 120 publications and 15 patents in the areas of ion channels and regenerative medicine. Her first book for nonscientists, Billys Halo, was shortlisted for the Mind Book of the Year Award (2007), a literary award which celebrates writing that contributes to public understanding of mental health issues. Dr. McKernan earned her bachelors degree in pharmacology with biochemistry from Kings College London and received a Ph.D. in biochemical pharmacology from the University of London.

About Cerevel TherapeuticsCerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company seeks to unlock the science surrounding new treatment opportunities through understanding the neurocircuitry of neuroscience diseases and associated symptoms. Cerevel Therapeutics has a diversified pipeline comprising four clinical-stage investigational therapies and several pre-clinical compounds with the potential to treat a range of neuroscience diseases, including Parkinsons, epilepsy, schizophrenia and substance use disorders. Headquartered in Cambridge, Mass., Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions. For more information, visit http://www.cerevel.com.

Special Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements that are based on managements beliefs and assumptions and on information currently available to management. In some cases, you can identify forward-looking statements by the following words: may, will, could, would, should, expect, intend, plan, anticipate, believe, estimate, predict, project, potential, continue, ongoing or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements about our potential to become a premier neuroscience company. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

Media Contact:Rachel EidesW2O purereides@purecommunications.com

Investor Contact:Matthew CalistriCerevel Therapeuticsmatthew.calistri@cerevel.com

Read more:
Cerevel Therapeutics Announces the Appointment of Dr. Ruth McKernan to its Board of Directors - GlobeNewswire

Timeline of key events in McMaster’s investigation in its Department of Psychology, Neuroscience and Behaviour – TheSpec.com

Investigation into McMaster's psychology department and sexual violence on campus

For nearly a year, McMaster has been investigating serious allegations of sexual assault and sexual harassment involving individuals in its Department of Psychology, Neuroscience and Behaviour (PNB).

On Thursday, the university released a report on the findings of a review into the department. The report found there are systemic and cultural issues within the PNB, including numerous reports of sexual harassment, and a degree of complacency that has let inappropriate behaviours go unchecked.

But while the report into the culture of the department is now complete, investigations into the more serious allegations of sexual harassment and sexual violence remain ongoing.

Below is a timeline of the events in 2020 that unfolded leading up to this weeks report.

Feb. 19: Maureen J. MacDonald, dean of science, sends an email to the PNB department and students affected by the situation stating a professor in the department has been suspended and barred from campus following serious allegations that possibly involve a number of university policies, including the sexual violence policy.

March 19: The Spectator obtains a copy of MacDonalds letter and confirms police are investigating Scott Watter, a professor in McMasters PNB department. Watters lawyer confirms his client has been placed on nondisciplinary leave of absence without loss of pay pending the outcome of an investigation into alleged breaches of university policies.

June 18: Police put out a release saying Watter, 46, is facing charges of sexual assault and sexual assault causing bodily harm for incidents that occurred in 2017 involving a female student. Police say they believe there may be other victims.

July 27: McMaster retains Rubin Thomlinson LLP, a law firm specializing in workplace investigations, to conduct a systemic review of the Department of Psychology, Neuroscience and Behaviour.

July 28: McMaster announces its original investigation under the universitys sexual violence and discrimination and harassment policies is being broadened to identify any potential systemic or cultural issues within the department that need to be surfaced and addressed. The broadened investigation is the climate review.

The university also announces it has suspended two more department faculty members. The faculty members are also banned from campus. They are not named, nor is anyone else sanctioned by the university in coming months. The university also does not provide details regarding the allegations levelled against the faculty members, nor does it provide details of allegations against those sanctioned.

Aug. 6: McMaster says a graduate student has been suspended and is no longer allowed on campus. The decision came after new allegations came to light relating to the universitys sexual violence and discrimination and harassment policies.

Aug. 21: McMaster says it has restricted another faculty member from interacting with students after new allegations were made under the universitys discrimination and harassment policy.

Sept. 30: McMaster says a former staff member in the PNB department who now works in another area of the university is on a leave of absence after a complaint about an alleged past sexual assault. The person is also banned from campus. Additionally, a second person who is a current department staff member was barred from interacting with students due to a separate allegation. The university said it was investigating both incidents under the universitys sexual violence policy.

Dec. 3: The university announces the review is complete and releases a report on its findings. The review uncovered systemic and cultural issues, including allegations of sexual harassment and a lack of boundaries between students and faculty, and a degree of complacency that has let inappropriate behaviours go unchecked, the report states.

Loading...Loading...Loading...Loading...Loading...

On Dec. 24: Watter is next scheduled to appear in court.

Moving forward: The university says that it will implement such measures as additional trauma-informed training for department staff and faculty. For students, it will offer training on sexual harassment, including providing information on accessing support. Equity, diversity and inclusion expertise will be provided to the department. The university will also commit to helping the department build on its research and teaching strengths.

Here is the original post:
Timeline of key events in McMaster's investigation in its Department of Psychology, Neuroscience and Behaviour - TheSpec.com